CA
NZ
UK
AU
IND
US
Rayonier Advanced Materials Inc. (NYSE:RYAM) moved higher in pre-market trading after appointing Daniel M. Krawczyk as president and chief executive officer, effective immediately.
The biotechnology-focused royalty and licensing company said the notes will be offered in a private placement to qualified institutional buyers under Rule 144A of the Securities Act. Ligand Pharmaceuticals (NASDAQ: LGND) also expects to grant initial purchasers a 13-day option to acquire up to …
The randomized, double-blind, placebo-controlled study evaluated a single 100 µg dose of DT120 (lysergide) orally disintegrating tablet (ODT) in adult patients diagnosed with MDD. The trial successfully met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in Montgomery–Åsberg Depression Rating Scale …
Under the terms of the agreement, AbbVie (NYSE: ABBV) will acquire Apogee Therapeutics (NASDAQ: APGE) for $135.11 per share in cash, representing a substantial premium to the company's previous closing price. The transaction has been unanimously approved by the boards of directors of both …
Nutriband Inc. (NASDAQ:NTRB) rose 6.21% in pre-market trading on June 22, reaching USD 3.08 after closing at USD 2.90 on June 18.
Under the terms of the transaction, CervoMed (NASDAQ: CRVO) agreed to sell 2,500,000 shares at a purchase price of $4.00 per share, generating approximately $10.0 million in gross proceeds before fees and expenses. The company stated that it plans to use the net proceeds …
Chevron Corporation (NYSE:CVX) rose about 1.22% in pre-market trading on June 22, reaching USD 175.75 after closing at USD 173.63 on June 18.
The biggest story in biotechnology was undoubtedly AbbVie’s (NYSE: ABBV) agreement to acquire Apogee Therapeutics (NASDAQ: APGE) for approximately $10.9 billion in cash.
The transaction assigns Sarborg an implied valuation of approximately $638.3 million, a figure that has significantly altered perceptions of CDT Equity’s (NASDAQ: CDT) underlying asset value. Based on its ownership of 1,020 Sarborg shares, CDT’s stake is now estimated to be worth roughly $127.5 …
The standout result was the durability and magnitude of patient responses after one year of treatment. MoonLake Immunotherapeutics (NASDAQ: MLTX) reported that 67.2% of patients achieved HiSCR75, a key measure indicating a 75% reduction in inflammatory lesions. The outcome compares favorably with historical performance …
Please wait processing your request...